Drug Identity
Finerenone is the generic name for the medication, while Kerendia® is the brand name used commercially 1, 2
Kerendia® (finerenone) is a first-in-class, orally administered, selective, nonsteroidal mineralocorticoid receptor antagonist (MRA) developed by Bayer HealthCare Pharmaceuticals 2
FDA Approval and Indication
Finerenone/Kerendia® received FDA approval in the United States to reduce the risk of sustained eGFR decline, end-stage renal disease, cardiovascular death, nonfatal myocardial infarction, and hospitalization for heart failure in adults with chronic kidney disease associated with type 2 diabetes 2
The medication is indicated specifically for adults with type 2 diabetes and chronic kidney disease with albuminuria (ACR ≥30 mg/g) despite maximum tolerated doses of renin-angiotensin system inhibitors, with eGFR ≥25 mL/min/1.73 m² and normal serum potassium 3
Clinical Context
Finerenone is classified as a nonsteroidal MRA, distinguishing it from older steroidal MRAs like spironolactone and eplerenone 4
The drug provides dual cardiorenal protection, reducing both kidney disease progression (23% reduction in composite kidney outcomes) and cardiovascular events (13% reduction in cardiovascular endpoints) 3, 5